Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

XOMA Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- ACQUISITION PROVIDES XOMA ROYALTY WITH POTENTIAL MILESTONE AND ROYALTYPAYMENTS UNDER GENERATION BIO'S COLLABORATION WITH MODERNA -

XOMA ROYALTY ENTERS INTO AGREEMENT TO ACQUIRE GENERATION BIO

EMERYVILLE, CALIF., DEC. 05, 2025 (GLOBE NEWSWIRE) -- XOMA ROYALTY CORPORATION (XOMA ROYALTY) (NASDAQ: XOMA), THE BIOTECH ROYALTY AGGREGATOR, TODAY ANNOUNCED IT HAS SUCCESSFULLY COMPLETED ITS PREVIOUSLY ANNOUNCED ACQUISITION OF THE ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF MURAL ONCOLOGY PLC (MURAL) (NASDAQ: MURA) (THE ACQUISITION) PURSUANT TO AN IRISH HIGH COURT SANCTIONED SCHEME OF ARRANGEMENT UNDER CHAPTER 1 OF PART 9 OF THE COMPANIES ACT 2014 OF IRELAND (THE SCHEME). MURAL SHAREHOLDERS RECEIVED $2.035 IN CASH PER SHARE (THE CONSIDERATION).

XOMA ROYALTY ANNOUNCES CLOSING OF TRANSACTION TO ACQUIRE MURAL ONCOLOGY PLC

WALTHAM, MASS. AND DUBLIN, DEC. 05, 2025 (GLOBE NEWSWIRE) -- MURAL ONCOLOGY PLC, (NASDAQ: MURA) (MURAL) ANNOUNCES THAT THE SCHEME OF ARRANGEMENT BETWEEN MURAL AND ITS SHAREHOLDERS UNDER CHAPTER 1 OF PART 9 OF THE COMPANIES ACT 2014 (THE SCHEME) PURSUANT TO WHICH XRA 5 CORP. (SUB), A WHOLLY-OWNED SUBSIDIARY OF XOMA ROYALTY CORPORATION (NASDAQ: XOMA) (XOMA ROYALTY) WILL ACQUIRE THE ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF MURAL, BECAME EFFECTIVE TODAY, 5 DECEMBER 2025 (THE EFFECTIVE DATE).

MURAL ONCOLOGY ANNOUNCES EFFECTIVENESS OF SCHEME OF ARRANGEMENT AND COMPLETION OF ACQUISITION

WALTHAM, MASS. AND DUBLIN, DEC. 03, 2025 (GLOBE NEWSWIRE) -- MURAL ONCOLOGY PLC, (NASDAQ: MURA) (MURAL)ANNOUNCES THAT THE HIGH COURT OF IRELAND HAS TODAY SANCTIONED THE SCHEME OF ARRANGEMENT BETWEEN MURAL AND ITS SHAREHOLDERS UNDER CHAPTER 1 OF PART 9 OF THE COMPANIES ACT 2014 (THE SCHEME) PURSUANT TO WHICH XRA 5 CORP. (SUB), A WHOLLY-OWNED SUBSIDIARY OF XOMA ROYALTY CORPORATION (NASDAQ: XOMA) (XOMA ROYALTY), WILL ACQUIRE THE ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF MURAL (THE ACQUISITION).

MURAL ONCOLOGY ANNOUNCES SANCTION OF THE SCHEME BY THE HIGH COURT

WALTHAM, MASS. AND DUBLIN, IRELAND, NOV. 26, 2025 (GLOBE NEWSWIRE) -- MURAL ONCOLOGY PLC (NASDAQ: MURA) (MURAL)ANNOUNCES THAT, IN ACCORDANCE WITH THE TERMS OF THE TRANSACTION AGREEMENT BETWEEN XOMA ROYALTY CORPORATION (NASDAQ: XOMA) (XOMA ROYALTY), XRA 5 CORP. (SUB) AND MURAL ANNOUNCED ON AUGUST 20, 2025 (THE TRANSACTION AGREEMENT), THE ADDITIONAL PRICE PER SHARE (AS DEFINED IN THE TRANSACTION AGREEMENT) HAS BEEN FINALLY DETERMINED IN ACCORDANCE WITH CLAUSE 2.4 OF THE TRANSACTION AGREEMENT AS $0.000. AS A RESULT, THE TOTAL CASH CONSIDERATION PAYABLE TO MURAL SHAREHOLDERS ON CLOSING OF THE ACQUISITION (AS DEFINED BELOW) WILL BE $2.035 IN CASH PER SHARE.

MURAL ONCOLOGY ANNOUNCES FINAL CASH CONSIDERATION PAYABLE ON CLOSING OF ACQUISITION BY XOMA ROYALTY

EMERYVILLE, CALIF., NOV. 21, 2025 (GLOBE NEWSWIRE) -- XOMA ROYALTY CORPORATION (XOMA ROYALTY) (NASDAQ: XOMA) TODAY ANNOUNCED IT HAS SUCCESSFULLY COMPLETED ITS PREVIOUSLY ANNOUNCED ACQUISITION OF ALL THE OUTSTANDING COMMON SHARES OF LAVA THERAPEUTICS N.V.

XOMA ROYALTY ANNOUNCES CLOSING OF TRANSACTIONS TO ACQUIRE LAVA THERAPEUTICS N.V.

BUSINESS DEVELOPMENT : SECURES ROYALTY ECONOMIC INTERESTS IN TWO EARLY STAGE PARTNERED ASSETS THROUGH XOMA ROYALTY'S ANNOUNCED EXPECTED ACQUISITION OF LAVA THERAPEUTICS.

XOMA ROYALTY REPORTS THIRD QUARTER AND YEAR TO DATE 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS

UTRECHT, THE NETHERLANDS AND PHILADELPHIA, NOV. 10, 2025 (GLOBE NEWSWIRE) -- LAVA THERAPEUTICS N.V. (LAVA) (NASDAQ: LVTX) TODAY ANNOUNCED A REMINDER TO LAVA SHAREHOLDERS RELATED TO THE PROPOSED TRANSACTION WITH XOMA ROYALTY CORPORATION (XOMA) (NASDAQ: XOMA).

LAVA THERAPEUTICS N.V. SHAREHOLDERS ARE REMINDED TO TENDER SHARES FOR XOMA ROYALTY TRANSACTION BEFORE NOVEMBER 12, 2025 DEADLINE

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

MURAL ONCOLOGY ANNOUNCES THAT MURAL SHAREHOLDERS APPROVE THE PROPOSED ACQUISITION BY XRA 5 CORP., A WHOLLY OWNED SUBSIDIARY OF XOMA ROYALTY

- AMENDMENT INCLUDES FINALIZED CASH AMOUNT AND UPDATED CVR TERMS FOR TENDER OFFER - LAVA ANNOUNCES NEW DATE FOR EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS EMERYVILLE, CALIF. AND UTRECHT, THE NETHERLANDS AND PHILADELPHIA, PENN.

XOMA ROYALTY AND LAVA THERAPEUTICS ANNOUNCE AMENDMENT TO PURCHASE AGREEMENT

EMERYVILLE, CALIF. AND UTRECHT, THE NETHERLANDS AND PHILADELPHIA, OCT. 02, 2025 (GLOBE NEWSWIRE) -- XOMA ROYALTY CORPORATION (XOMA ROYALTY) (NASDAQ: XOMA) AND LAVA THERAPEUTICS N.V.

XOMA Corporation

XOMA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

XOMA Corporation

XOMA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

XOMA